.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FF04_Avelumab.Avelumab

Information

Avelumab is a fully human monoclonal antibody of the IgG1 isotype that targets programmed death-ligand 1 (PD-L1). It is approved for the treatment of metastatic Merkel cell carcinoma and advanced or metastatic urothelial carcinoma. It functions as an immune checkpoint inhibitor, enhancing T-cell mediated immune response against cancer cells.

Pharmacokinetics

Pharmacokinetics in adult cancer patients following intravenous administration; parameters are based on population PK analysis in patients with advanced solid tumors, median age 64 years (range 20–89).

References

1. Vugmeyster, Y, et al., & Khandelwal, A (2022). Avelumab Dose Selection for Clinical Studies in Pediatric Patients with Solid Tumors. Clinical pharmacokinetics 61(7) 985–995. DOI:10.1007/s40262-022-01111-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35484319

2. Masters, JC, et al., & Brar, S (2022). Model-informed drug development supporting the approval of the avelumab flat-dose regimen in patients with advanced renal cell carcinoma. CPT: pharmacometrics & systems pharmacology 11(4) 458–468. DOI:10.1002/psp4.12771 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35166465

3. Heery, CR, et al., & Gulley, JL (2017). Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. The Lancet. Oncology 18(5) 587–598. DOI:10.1016/S1470-2045(17)30239-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28373007

Revisions

• 06/2025 initial generated model